Ikorel
(Nicorandil)ApprovedSmall molecule
Merck & Co.Nicorandil is used to treat angina (chest pain caused by reduced blood flow to the heart). It helps relieve chest pain and improves the ability to exercise by widening blood vessels and reducing the heart's workload.[2] Ikorel is currently approved and in use across 14 indications[4].[1]
Ikorel is one of 311 small molecule programs targeting Insulin resistance. It is currently in Approved.
14
Indications
27
Total Trials
6
Active Trials
310
Competitors
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 12 indications
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Ikorel
Merck & Co.Approved
Spikevax
ModernaPreclinical
Bnt162b2
BioNTechPreclinical
COVID-19 Vaccine
ModernaPreclinical
Biaxin
AbbViePreclinical
Stivarga
BayerPreclinical
Aimovig
AmgenPreclinical
Aldactone
PfizerPreclinical
Nexavar
BayerPreclinical
Singulair
AstraZenecaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Coronary Artery Disease3 trials
Efficacy2 trials
Acute Myocardial Infarction2 trials
Myocardial Infarction2 trials
Effect of Nicorandil for the Patients of Acute ST Segment Elevation Myocardial Infarction
Unknown status·—·Phase 4·NCT02435797·100 enrolled
Effect of Nicorandil on Cardiac Sympathetic Nerve for the Patients of Acute ST Segment Elevation Myocardial Infarction
Unknown status·—·Phase 4·NCT04826497·80 enrolled
Injury1 trial
Intracoronary of Nicorandil and Verapamil to Reduce the Occurrence of Periprocedural Myocardial Injury
Unknown status·TThe First Affiliated Hospital of Zhejiang Chinese Medical University·Phase 2·NCT05399576·150 enrolled
16 more indications
Angina Pectoris1 trial
Chronic Stable Angina1 trial
Radiation Pneumonitis1 trial
Chronic Total Occlusion1 trial
Microvascular Dysfunction1 trial
Effects of Nicorandil on Microvascular Dysfunction in Patients With STEMI Undergoing Primary PCI
Not yet recruiting·CChina National Center for Cardiovascular Diseases·Phase 4·NCT06787430·170 enrolled
Prevention1 trial
Oral Nicorandil for Prevention of No Reflow Phenomenon in Anterior STEMI Patients Undergoing PPCI
Completed·—·Phase 1/2·NCT07138508·300 enrolled
ST Elevation Myocardial Infarction1 trial
Percutaneous Coronary Intervention (PCI)1 trial
Percutaneous Coronary Intervention1 trial
Heart Disease1 trial
Treatment1 trial
Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging
Active, not recruiting·—·Phase 2·NCT04120766·64 enrolled
Coronary Artery Bypass Graft1 trial
Unspecified2 trials
China-Administration of Nicorandil Group（CHANGE）
Completed·—·Phase 4·NCT03445728·238 enrolled
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Ikorel drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Nicorandil. EMBL-EBI & Wellcome Sanger Institute.
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company